Axatilimab with CAR-T for high-risk lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests whether adding a drug called axatilimab to the standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. CAR-T is a treatment that uses your own immune cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lymphoma called large B-cell lymphoma.
- You have at least one high-risk feature of the disease.
- You are eligible for CAR-T therapy as approved by the FDA.
- Your cancer can be seen on a CT or PET scan.
- Your organs are working well enough, including heart, lungs, kidneys, and liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.